Pancreatic cancer is one of the deadliest forms of the disease, with an average five-year survival rate of 7% has just been brought to the top of the priority list for Berg, a small Boston-based biotech firm. The firm plans to team up with multiple hospitals and other research teams to research and validate the first clinical landmark to diagnose and treat pancreatic cancer. The firm has partnered with some of the most prestigious hospitals and Universities such as Beth Israel Deaconess Medical Center, Harvard University Med School and the Pancreatic Cancer Research Team to name a few.
Bergs’ research has led them to their first drug development, BPM31510. BPM31510 is currently in clinical trials. This drug focuses on revamping the metabolism of the actual cancer cells, and re-teaches them how to endure apoptosis, also known as cell death. What’s interesting about BPM31510 is that the cancer cells with be killed naturally, which is a relief when one thinks about the side effects of chemotherapy.
Big Pharma companies are not quick to jump on board for reasons so simple as the degree of difficulty to actually find a cure for cancer is extremely high. Biotech and Pharmaceutical companies would rather direct their attention and money towards rare diseases, where they have a higher profit margin. As the fight to cure cancer continues, companies like Berg’s are up for the challenge as they look forward to getting past phase II clinical trials for pancreatic cancer at Approx. 48 PCRT sites worldwide.